Neurotoxicity is not enhanced by increased dose intensities of cisplatin administration.

[1]  L. L. Stevenson,et al.  Progressive paresthesias after cessation of therapy with very high-dose cisplatin , 2004, Cancer Chemotherapy and Pharmacology.

[2]  J. Verweij,et al.  Asbestos bodies and fibers in lung tissue , 1974, Environmental Health Perspectives.

[3]  G. Cavaletti,et al.  Cisplatin‐lnduced peripheral neurotoxicity is dependent on total‐dose intensity and single‐dose intensity , 1992, Cancer.

[4]  R. Lipton,et al.  Large and small fibre type sensory dysfunction in patients with cancer. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[5]  C. Vecht,et al.  ORG 2766 in the Prevention of Cisplatin Neuropathy , 1991 .

[6]  S. Howell.  Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy , 1991, Springer US.

[7]  R. G. van der Hoop,et al.  Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin , 1990, Cancer.

[8]  J. Hainsworth,et al.  High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. C. Houwelingen,et al.  Prevention of cisplatin neurotoxicity with an ACTH (4–9) analogue in patients with ovarian cancer , 1990 .

[10]  R. Hoop,et al.  Vibration perception and thermoperception as quantitative measurements in the monitoring of cisplatin induced neurotoxicity , 1989, Journal of the Neurological Sciences.

[11]  E. Perez,et al.  Cisplatin dose intensity in non-small cell lung cancer: phase II results of a day 1 and day 8 high-dose regimen. , 1989, Journal of the National Cancer Institute.

[12]  Roy E. Furman,et al.  Cisplatin neuropathy. Risk factors, prognosis, and protection by WR‐2721 , 1988, Cancer.

[13]  L. McCluskey,et al.  Unusual presentation of cis‐platinum Neuropathy , 1988, Neurology.

[14]  S. Iacobelli,et al.  High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients. , 1987, Cancer treatment reports.

[15]  D. Gandara,et al.  High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Legha,et al.  High-dose cisplatin administration without hypertonic saline: observation of disabling neurotoxicity. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Y. Ostchega,et al.  High-dose cisplatin in hypertonic saline in refractory ovarian cancer. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Jones,et al.  High‐dose cisplatin in patients with advanced malignancies , 1985, Cancer.

[19]  L. Davis,et al.  Cisplatin neuropathy. Clinical, electrophysiologic, morphologic, and toxicologic studies , 1984, Cancer.

[20]  J. Rogin,et al.  Peripheral sensory neuropathy and cisplatin chemotherapy , 1984, Neurology.

[21]  K. Jabboury,et al.  Cis‐diamminedichloroplatinum (II) by 5‐day continuous infusion a new dose schedule with minimal toxicity , 1984, Cancer.

[22]  J. Wharton,et al.  Single-Agent cis-Platinum Therapy for Advanced Ovarian Cancer , 1981, Obstetrics and gynecology.

[23]  C. Cohen,et al.  High-dose platinum for the treatment of refractory ovarian cancer. , 1981, Gynecologic oncology.

[24]  J. Goldberg,et al.  Standardised method of determining vibratory perception thresholds for diagnosis and screening in neurological investigation. , 1979, Journal of neurology, neurosurgery, and psychiatry.

[25]  J. Hildebrand,et al.  The neuromuscular function in patients with malignant tumours. Electromyographic and histological study. , 1967, Brain : a journal of neurology.